Earnings summaries and quarterly performance for Marker Therapeutics.
Executive leadership at Marker Therapeutics.
Board of directors at Marker Therapeutics.
Research analysts who have asked questions during Marker Therapeutics earnings calls.
Matthew Biegler
Oppenheimer & Co. Inc.
4 questions for MRKR
Also covers: ALLO, ARVN, CTMX +2 more
Tony Butler
Rodman & Renshaw
3 questions for MRKR
Also covers: ADAP, CGEN, GTBP +1 more
JH
Jackson Harvey
Nomura
2 questions for MRKR
Yun Zhong
Wedbush Securities
2 questions for MRKR
Also covers: ASND, MNKD, PASG +2 more
JF
Jordyn Fantuzzi
Piper Sandler
1 question for MRKR
JC
Joseph Catanzaro
Wolfe Research, LLC
1 question for MRKR
Also covers: AADI, CPRX, CRDF +7 more
Kristen Kluska
Cantor Fitzgerald
1 question for MRKR
Also covers: ABEO, ADMA, AQST +24 more
TT
Ted Tenthoff
Piper Sandler & Co.
1 question for MRKR
Also covers: ARVN, CLRB, CUE +1 more
Recent press releases and 8-K filings for MRKR.
Marker Therapeutics' Pancreatic Cancer Study Receives National Attention
MRKR
New Projects/Investments
- Marker Therapeutics' Multi-Antigen Targeted T cell (MAR-T cell) technology, developed at Baylor College of Medicine, was featured on Good Morning America on January 22, 2026, highlighting a Baylor-led clinical study in pancreatic cancer.
- The Baylor College of Medicine Phase 1/2 pancreatic cancer study demonstrated a favorable safety profile and achieved an 84.6% disease control rate when combining Multi-Antigen Targeted T cells with frontline chemotherapy.
- Marker Therapeutics plans to initiate a Company-sponsored pancreatic cancer study (NCT06549751) in the first half of 2026, aiming to build on the encouraging results from the Baylor study.
- The company's pancreatic cancer program has received funding from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program and the Cancer Prevention and Research Institute of Texas (CPRIT).
Jan 26, 2026, 12:00 PM
Marker Therapeutics Announces Promising Pancreatic Cancer Study Results
MRKR
New Projects/Investments
- A Phase 1/2 clinical study from Baylor College of Medicine demonstrated a favorable safety profile and an 84.6% disease control rate in patients with pancreatic cancer in Arm A, with a median overall survival rate of 14.1 months.
- The study highlighted a correlation between the clinical benefit and the expansion and persistence of Multi-Antigen Targeted T cells.
- Marker Therapeutics anticipates initiating its pancreatic cancer program in the first half of 2026, building on these results and incorporating improvements from its MT-601 lymphoma study.
- This pancreatic cancer program is supported by non-dilutive funding from the National Institutes of Health (NIH) and the Cancer Prevention and Research Institute of Texas (CPRIT), which is expected to allow the company to proceed without affecting its financial runway.
Jan 5, 2026, 12:00 PM
Marker Therapeutics Reports Q3 2025 Financial Results and Business Updates
MRKR
Earnings
Guidance Update
New Projects/Investments
- Marker Therapeutics reported a net loss of $2.0 million for the third quarter ended September 30, 2025, an improvement from a net loss of $2.3 million for the same period in 2024.
- As of September 30, 2025, the company held $17.6 million in cash and cash equivalents, and $1.4 million in restricted cash, with existing funds expected to support operations through Q3 2026. This cash runway was extended by raising approximately $10 million through an ATM facility.
- Positive clinical data from the Phase 1 APOLLO study for MT-601 in relapsed Non-Hodgkin lymphoma patients demonstrated a 66% objective response rate and 50% complete response rate, with further clinical data anticipated in the first half of 2026.
- Key operational milestones include treating the first patient in the Off-the-Shelf program (RAPID study) for Acute Myeloid Leukemia or Myelodysplastic Syndrome and establishing a cGMP manufacturing collaboration with Cellipont Bioservices for MT-601 production.
Nov 14, 2025, 12:20 PM
Marker Therapeutics Announces Encouraging Phase 1 APOLLO Study Results for MT-601
MRKR
- Marker Therapeutics (MRKR) will present preliminary efficacy and safety data from its Phase 1 APOLLO study of MT-601 at the 67th American Society of Hematology (ASH) Annual Meeting from December 6-9, 2025.
- The study demonstrated an objective response rate (ORR) of 66% with 50% complete response (CR) in patients with Non-Hodgkin lymphoma (NHL), and an ORR of 78% with 11% CR in Hodgkin lymphoma (HL).
- MT-601 exhibited a robust safety profile, reporting no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS).
- Based on these favorable outcomes, the company has advanced MT-601 to the dose expansion phase for patients with Diffuse Large B Cell Lymphoma (DLBCL).
Nov 3, 2025, 2:15 PM
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
MRKR
Product Launch
New Projects/Investments
- Marker Therapeutics, Inc. announced on October 6, 2025, that the first patient has been treated in its Off-the-Shelf (OTS) Program evaluating MT-401, a Multi-Antigen Recognizing (MAR)-T cell therapy, in a Phase 1 RAPID study.
- The initial patient tolerated the therapy well with no treatment-related adverse events, which is consistent with the favorable safety profile previously reported for MAR-T cells.
- The OTS product aims to provide a fast treatment option for patients with aggressive diseases, potentially expediting treatment to as fast as 72 hours, and enabling broader scalability and accessibility of cell therapies at a lower per-dose cost.
- The OTS program is supported by non-dilutive funding from the Food and Drug Administration (FDA), the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program, and the Cancer Prevention and Research Institute of Texas (CPRIT), which will not affect the company's financial runway or its efforts on its lead asset, MT-601.
Oct 6, 2025, 11:30 AM
Marker Therapeutics Provides Positive Phase 1 Clinical Update for MT-601 in Relapsed Lymphoma
MRKR
Product Launch
New Projects/Investments
- Marker Therapeutics reported positive Phase 1 clinical results for MT-601 in relapsed lymphoma from its APOLLO study, demonstrating a 50% complete response rate and 66% overall response rate in non-Hodgkin lymphoma patients.
- The study highlighted an excellent safety profile for MT-601, with no dose-limiting toxicities or ICANS, and only mild (Level 1) Cytokine Release Syndrome observed, even at the highest dose of 400 million cells.
- Responses were durable, with three patients achieving complete response for over a year and five patients showing clinical benefit for over six months, despite being heavily pretreated, including prior CAR T-cell therapy and bispecifics.
- The company plans to proceed with a dose expansion phase for DLBCL CAR relapse and bispecific relapse patients, which will form the basis for a future pivotal study, with the goal of seeking accelerated approval.
Aug 26, 2025, 2:10 PM
Quarterly earnings call transcripts for Marker Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more